Ja Young Kim, NP
Nurse Practitioner · Sunnyvale
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 9 years
- Graduated 2017
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Ja Young Kim’s office at (408) 885-5000 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Medicaid work
$113 in 2024
Medicaid paid $113 for 178 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 13 | $113 |
| Pain severity quantified; no pain present (COA) (ONC) | 12 | $0 |
| Medication list documented in medical record (COA) | 70 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 14 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 69 | $0 |
| 2024 | 178 | 5 | 19 | $113 |
| 2023 | 40 | 3 | 15 | $537 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 13 | $537 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 12 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 15 | $0 |
Drugs they prescribed that Part D paid
$1,360,000
Pharmacies billed $1,360,000 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,243) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
1,658 generic and 1,413 brand-name prescriptions · $1,360,000 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 357 | $504,818 | $1,414 |
| Ozempic | 273 | $242,071 | $887 |
| Tradjenta | 156 | $192,878 | $1,236 |
| Trulicity | 193 | $185,095 | $959 |
| Rybelsus | 38 | $43,362 | $1,141 |
See all 35 drugs
| Jardiance | 357 | $504,818 | $1,414 |
| Ozempic | 273 | $242,071 | $887 |
| Tradjenta | 156 | $192,878 | $1,236 |
| Trulicity | 193 | $185,095 | $959 |
| Rybelsus | 38 | $43,362 | $1,141 |
| Mounjaro | 37 | $36,607 | $989 |
| Semglee (Yfgn) | 80 | $35,393 | $442 |
| Januvia | 21 | $28,069 | $1,337 |
| Fiasp Flextouch | 22 | $11,989 | $545 |
| Basaglar Kwikpen U-100 | 53 | $11,560 | $218 |
| Ultra-Fine Mini Pen Needle | 73 | $5,374 | $74 |
| Ultra-Fine Short Pen Needle | 61 | $4,556 | $75 |
| Glipizide | 199 | $4,135 | $21 |
| Lantus Solostar | 45 | $3,592 | $80 |
| Tresiba Flextouch U-100 | 13 | $2,674 | $206 |
| Metformin | 339 | $2,493 | $7 |
| Novolin 70-30 | 19 | $2,487 | $131 |
| Novolog Flexpen | 13 | $2,270 | $175 |
| Atorvastatin | 314 | $2,124 | $7 |
| Novolin 70-30 Flexpen | 11 | $1,783 | $162 |
| Fosinopril | 60 | $1,199 | $20 |
| Losartan | 172 | $1,122 | $7 |
| Metformin Hcl Er | 82 | $957 | $12 |
| Glipizide Er | 36 | $819 | $23 |
| Insulin | 13 | $726 | $56 |
| Amlodipine Besylate | 136 | $462 | $3 |
| Benazepril | 35 | $335 | $10 |
| Metoprolol | 28 | $334 | $12 |
| Simvastatin | 59 | $263 | $4 |
| Rosuvastatin | 23 | $208 | $9 |
| Atenolol | 39 | $198 | $5 |
| Lisinopril | 27 | $178 | $7 |
| Pravastatin | 15 | $96 | $6 |
| Metoprolol | 12 | $94 | $8 |
| Hydrochlorothiazide | 46 | $89 | $2 |
Year by year
| 2024 | 3,243 | 190 | 0% (0) | 44% | $1,360,000 |
| 2023 | 2,104 | 160 | 0% (0) | 49% | $1,118,468 |
| 2022 | 372 | 81 | None | 31% | $222,352 |
| 2021 | 176 | 60 | None | 19% | $32,465 |
| 2020 | 111 | 52 | None | 10% | $5,361 |
| 2019 | 42 | 28 | 0% (0) | None | $774 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 30 drugs
| Jardiance | 237 | $372,887 | $1,573 |
| Trulicity | 243 | $248,977 | $1,025 |
| Tradjenta | 117 | $165,658 | $1,416 |
| Ozempic | 87 | $81,553 | $937 |
| Januvia | 16 | $28,187 | $1,762 |
| Novolog Flexpen | 42 | $24,668 | $587 |
| Semglee (Yfgn) | 45 | $22,686 | $504 |
| Lantus Solostar | 38 | $21,101 | $555 |
| Basaglar Kwikpen U-100 | 51 | $17,433 | $342 |
| Humalog | 16 | $15,422 | $964 |
| Novolin 70-30 | 20 | $7,291 | $365 |
| Ultra-Fine Mini Pen Needle | 56 | $6,029 | $108 |
| Novolin 70-30 Flexpen | 12 | $5,567 | $464 |
| Metformin | 221 | $4,794 | $22 |
| Atorvastatin | 180 | $4,494 | $25 |
| Ultra-Fine Short Pen Needle | 45 | $4,077 | $91 |
| Glipizide | 160 | $4,053 | $25 |
| Tresiba Flextouch U-100 | 11 | $2,112 | $192 |
| Metformin Hcl Er | 42 | $1,518 | $36 |
| Losartan | 77 | $1,387 | $18 |
| Fosinopril | 33 | $1,051 | $32 |
| Insulin | 13 | $925 | $71 |
| Insulin | 12 | $837 | $70 |
| Simvastatin | 30 | $742 | $25 |
| Amlodipine Besylate | 44 | $545 | $12 |
| Metoprolol | 19 | $489 | $26 |
| Benazepril | 12 | $281 | $23 |
| Lisinopril | 12 | $250 | $21 |
| Hydrochlorothiazide | 35 | $151 | $4 |
| Single Use Swab | 12 | $37 | $3 |
2022: 9 drugs
| Biktarvy | 37 | $136,693 | $3,694 |
| Jardiance | 12 | $16,186 | $1,349 |
| Trulicity | 13 | $11,389 | $876 |
| Atorvastatin | 37 | $270 | $7 |
| Diclofenac | 12 | $265 | $22 |
| Losartan | 13 | $132 | $10 |
| Metformin | 11 | $113 | $10 |
| Lisinopril | 12 | $57 | $5 |
| Hydrochlorothiazide | 14 | $34 | $2 |
2021: 3 drugs
| Triumeq | 17 | $10,915 | $642 |
| Triamcinolone Acetonide | 11 | $82 | $7 |
| Hydrochlorothiazide | 11 | $33 | $3 |
Professional record
- NPI
- 1033611280
- Licence
- CA NP95008416
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2018-03-04
- NPI last updated
- 2019-07-12
This is when the NPI record was last certified, not a medical board exam.